VN Research & Consulting
 Like us on facebook  Follow us on twitter  Follow us on LinkedIn  IndiaNotes on Google Plus  IndiaNotes on Pinterest  IndiaNotes on Stumbleupon  Subscribe to our feeds


Stocks  A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Go
Feedback
You are here: IndiaNotes

Filter search : Quote Research All


Reports for search string : Affordability

LIC Housing Finance: CD Equisearch revise rating to 'Accumulate' and raise target price
According to CD Equisearch, the stock currently trades at 3.0x FY18e BV (16.3x FY18e EPS of Rs 45.51) and 2.5x FY19e BV (13.7x FY19e EPS of Rs 54.16). LICHFL's mortgage growth is likely to pick up wit...
CD Equisearch Pvt Ltd, 09 Jun 2017
Changing growth phases in real estate market
Alike any other business, the real estate sector has also experienced its highs and lows. The year 2017 comes with a new promise for the realtors as well as buyers that will contribute to the growth o...
Guest Author, 19 May 2017
The What, Why, and How of Consumer Durable Loans
Being a proud owner of small luxuries in life is no longer an impossible dream. You may easily upgrade your television or refrigerator, purchase a laptop, or install an air conditioner in the living r...
Guest Author, 19 Jan 2017
Aurobindo Pharma: Valuation gap will narrow going forward
Way2wealth believe the valuation gap will narrow going forward on the back of the company's strong US portfolio, synergies from recent acquisition & improving earnings visibility. At its CMP of 704.55...
Way2wealth, 12 Jan 2017
After a Bumpy 2016, Realty heads towards Consolidation
Real estate sector has faced chaotic times in 2016 and is staring at another challenging year ahead, following disturbance caused by reforms like the Real Estate Regulation Act (RERA) and Demonetizati...
Dynamic Equities Pvt Ltd, 05 Jan 2017
Thinking to Buy a Bike? Read the 8 Tips That Will Help You Choose the Best Option!
You may buy the bike on EMI to prevent any financial burden. Lenders today offer various benefits like flexible repayment schemes, quick loan approval, and minimal documentation.
Guest Author, 02 Dec 2016
GlaxoSmithKline Consumer Healthcare's Q2FY16 numbers disappointing; Accumulate
GSK 2Q results were disappointing with 3% decline in MFD volumes amidst continuous pressure on discretionary spending by the consumers. GSK is adopting an aggressive strategy to boost volumes. Retain ...
Prabhudas Lilladher, 10 Nov 2016
Lloyd Electric: Channel checks indicate strong volume growth and market share gains
Lloyd Electric and Engineering, one of the top four players in the industry, has witnessed strong growth over past 23 years, with its market share increasing to 13-14% in CY16 (<8% in CY13).
Motilal Oswal, 08 Nov 2016
Tata Steel: European consolidation strategy is on
Tata Steel on Friday said that it was continuing to pursue European consolidation strategy and was in talks with Thyssenkrupp AG for potential JV for European steel business, following alleged disclos...
Dynamic Equities Pvt Ltd, 01 Nov 2016
Indiabulls Hsg Fin: Transformation to focused mortgage player has yielded returns; maintain Buy
Following its credit rating upgrade to AAA in FY15, Indiabulls Hsg Fin has focused on capital market borrowings and reduced its dependence of bank borrowings. Over the past four quarters, the share of...
Motilal Oswal, 20 Sep 2016
J B Chemicals & Pharmaceuticals: 'Buy' rating maintained with an upward revised target
According to CD Equisearch, the stock currently trades at 18.3x FY17e EPS of Rs. 18.73 and 15x FY18e EPS of 22.81. We maintain our 'buy' rating on the stock with a target revised upwards from the prev...
CD Equisearch Pvt Ltd, 14 Sep 2016
Five easy steps to a home loan
Taking a home loan is not just a life altering decision, you are also making a commitment and establishing a long term relationship with your lender, so choose wisely and you will rep its benefits thr...
Rajiv Raj, 29 Aug 2016
Exide Industries: In its fourth successive year of profits; Buy on dips
The company is in its fourth successive year of profits. At CMP of Rs.178, the stock is trading at a P/E of 22.67. Dynamic Levels recommend a buy on this stock at correction at around 170 levels which...
Dynamic Equities Pvt Ltd, 29 Jul 2016
Narayana Hrudayalaya IPO - Investors are not Patient
NHL delivers high quality and affordable healthcare services by leveraging their economies of scale, skilled doctors, process improvements and an efficient business model. However margins are low. NHL...
Punit Jain, 17 Dec 2015
Narayana Hrudayalaya IPO: Subscribe with a very long-term investment horizon
Long-term prospects for the company are very bright but the IPO is demanding valuations which seem bit stretched. The company is trading at FY15 EV/EBIDTA (upper band) of 38.1. We suggest investors ma...
Way2wealth, 17 Dec 2015
TTK Healthcare to be 'Industry Partner' in project to develop Low Cost Prosthetic Heart Valves; Buy
PSG IMSR, Coimbatore is working on developing Low Cost Prosthetic Heart Valves for India in collaboration with Colorado State University (CSU) and The Ohio State University, funded through a grant fro...
Firstcall India Equity, 11 Dec 2015
Mangalam Drugs & Organics emerging as single-stop destination for frontline antimalarials, Buy
Mangalam Drugs & Organics is approved by Clinton Foundation USA under their fight against malaria programme for supply of antimalarial bulk drugs worldwide. Firstcall are recommending this scrip for m...
Firstcall India Equity, 28 Oct 2015
Real Estate Q2FY16: A Preview
Over 2QFY16, BSE Realty index underperformed the broader index by ~14% as macro outlook and on-ground recovery pace continued as major overhangs. Besides the delayed macro recovery push, real estate c...
Motilal Oswal, 26 Oct 2015
Buy Abbott India; Pharma sector to grow at CAGR of 20% over next 5 years
Abbott India's net sales rose by 21.66% from INR4,937.50m to INR6,007.10m y/y while its net profit increased 29.58% y/y from INR384m to INR497.6m in Q4FY15. Firstcall recommend this scrip for the mid-...
Firstcall India Equity, 07 Jul 2015
Claris Lifesciences to have 100 ANDAs in the US by 2018-19; Buy
Claris Lifesciences has filed for the 1 ANDa during the March quarter. It plans to file 18 ANDAs in the US during FY16. Firstcall recommend this scrip for the mid- to long- term.
Firstcall India Equity, 30 Jun 2015
View All

Intraday Tips

What are technical calls?

View Stock Advice by: